99.6% of target joints were resolved in adults on ELOCTATE prophy.‡
ELOCTATE is the #1 prescribed extended half-life Factor VIII in the US, with experience proven over 4 years of clinical trials.1
98.8% of patients were able to dose less frequently with ELOCTATE than their prior treatment while maintaining consistent total factor use. ¶
Talk to your doctor to see if ELOCTATE is right for you.
The recommended starting regimen is 50 IU/kg every 4 days as directed by your doctor. In children under 6 years of age, the recommended starting regimen is 50 IU/kg administered twice weekly. The regimen can be adjusted based on your body’s individual response.
*Median of 1.6 overall bleeds per year.
†ELOCTATE has been proven to help patients prevent bleeding episodes using a prophylaxis regimen.
‡Data from patients treating prophylactically with ELOCTATE for at least 12 months, who had target joints at enrollment in ASPIRE. 234 out of 235 target joints were resolved. A target joint is defined as a major joint with 3 or more bleeding episodes in a consecutive 6-month period. Target joint resolution is defined as 2 or less spontaneous bleeds in a 12-month period.
¶Data from a post-hoc analysis from A-LONG. Shapiro AD, Ragni MV, Kulkarni R, Oldenberg J, Srivastava A, Quon DV, Pasi KJ, Hanabusa H, Pabinger I, Mahlangu J, Fogarty P, Lillicrap D, Kulke S, Potts J, Neelakantan S, Nestorov I, Li S, Dumont JA, Jiang H, Brennan A, Pierce GF. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels. J Thromb Haemost 2014; 12: 1788–800
1#1 prescribed based on specialty pharmacy dispensing records beginning 2014 to present.
In a clinical study:
*Data from patients treating prophylactically with ELOCTATE for at least 12 months, who had target joints at enrollment in ASPIRE. 9 out of 9 target joints were resolved. A target joint is defined as a major joint with 3 or more bleeding episodes in a consecutive 6-month period. Target joint resolution is defined as 2 or less spontaneous bleeds in a 12-month period.
- Laith, an ELOCTATE PEER
Note: This is a personal account of an ELOCTATE Peer. Please talk to your healthcare provider about whether ELOCTATE may be right for you. Individual results may vary.
In a clinical trial, 98.8% of patients were able to dose less frequently with ELOCTATE than their prior treatment while maintaining consistent to total factor use.
With individualized dosing, ELOCTATE offers the potential for fewer infusions. Because every day makes a difference.
In clinical studies, ELOCTATE was shown to last 50% longer in the body than ADVATE®.2
ADVATE® [Antihemophilic Factor (Recombinant)] is a registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire Plc.
2 ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] Package Insert. Page 12. 2017.
Just as the blades of a windmill harness naturally occurring wind to produce energy, Fc Fusion utilizes naturally occurring Fc receptors in your body to keep Factor VIII temporarily recirculating in your bloodstream, protecting you from bleeds. ELOCTATE is Factor VIII fused with an Fc protein.
For the scientist in you, check out this video with a little more detail about how Fc Fusion works.Watch Video
You know you're leaving the ELOCTATE website?
If you're okay with that, we're okay with that.
Come back soon!
You’re being directed to the ELOCTATE Healthcare Professional website. If you’re okay with that, we’re okay with that.
Come back soon!
indications and important facts about eloctate
what is the most important information I should know about ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein]? You should not use ELOCTATE if you are allergic to ELOCTATE or any of its other ingredients. Tell your healthcare provider if you have had an allergic reaction to any Factor VIII product prior to using ELOCTATE.
Allergic reactions may occur. Call your healthcare provider or emergency department right away if you have any of the following symptoms: difficulty breathing, chest tightness, swelling of the face, rash or hives.
Your body can also make antibodies called "inhibitors" against ELOCTATE. This can stop ELOCTATE from working properly. Your healthcare provider may give you blood tests to check for inhibitors.
THE MOST COMMON SIDE EFFECTS OF ELOCTATE INCLUDE: headache, rash, joint pain, muscle pain and general discomfort. These are not all the possible side effects of ELOCTATE. Talk to your healthcare provider for more information and about any side effect that bothers you or does not go away.
WHAT SHOULD I TELL MY HEALTHCARE PROVIDER BEFORE STARTING ELOCTATE?
Tell your healthcare provider about all your health conditions, including if you:
AFTER STARTING ELOCTATE:
If your bleeding is not controlled and you experience a lack of clinical response to Factor VIII therapy, call your healthcare provider right away.
Medicines are sometimes prescribed for purposes other than those listed here. Do not use ELOCTATE for a condition for which it was not prescribed. Do not share ELOCTATE with other people, even if they have the same symptoms that you have.
ELOCTATE is an injectable medicine that is used to help control and prevent bleeding in people with Hemophilia A (congenital Factor VIII deficiency).
Your healthcare provider may give you ELOCTATE when you have surgery.
HOW SHOULD I RECEIVE ELOCTATE?
ELOCTATE should be administered as ordered by your healthcare provider. You should be trained on how to do infusions by your healthcare provider. Many people with hemophilia A learn to infuse ELOCTATE by themselves or with the help of a family member. See the booklet called "Instructions for Use" packaged in your ELOCTATE for directions on infusing. If you are unsure of the procedure, please ask your healthcare provider.
IMPORTANT FACTS ABOUT ELOCTATE
Please read this information carefully before using ELOCTATE and each time you get a refill, as there may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.
The risk information provided here is not comprehensive. To learn more, talk about ELOCTATE with your healthcare provider or pharmacist.
The FDA-approved product labeling can be found at www.eloctate.com or 1-855-MyELOCTATE (693-5628). You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Bioverativ Therapeutics Inc.
Waltham, MA 02451 USA
U.S. License #2078